GovBidAlerts
← All opportunities

Human Hindbrain Organoid Functional Assay Services.

Key dates

Posted
Sep 11, 2026
Response deadline
Sep 17, 2026, 2:30 PM UTC
Archive date
Oct 2, 2026
Archive type
auto15

Classification

Notice type
Combined Synopsis/Solicitation
Base type
Combined Synopsis/Solicitation
Set-aside
No Set aside used
Set-aside code
NONE
PSC
B504

NAICS

Issuing office

Department
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
FOOD AND DRUG ADMINISTRATION
Office
FDA OFFICE OF ACQ GRANT SVCS
Office code
Organization type
OFFICE
Office address
Rockville, MD, 20852, USA

Contacts

Description

The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Division of Applied Regulatory Science (DARS), intends to award a sole-source, Firm-Fixed-Price purchase order to OrganoTherapeutics SARL for Human iPSC-Derived Hindbrain Organoid Functional Assay Services. The requirement includes the provision of human induced pluripotent stem cell (iPSC)-derived hindbrain organoids and associated materials necessary to support in vitro research evaluating drug-induced effects on respiratory-relevant neural circuits. The contractor will also perform functional characterization of the organoids using three-dimensional multi-electrode array (3D MEA) technology to assess electrophysiological responses to drugs known to affect respiratory function. The functional characterization includes testing FDA-identified drug and reversal-agent combinations, MEA measurements, evaluation of batch-to-batch reproducibility, collection of exposed drug solutions for FDA verification, data analysis, and delivery of raw data, analyzed data, analysis files, and study reports. The requirement also includes twelve scheduled deliveries of human hindbrain organoids to the FDA White Oak Campus. The first delivery will consist of 96 organoids, with subsequent deliveries consisting of 48 organoids each. Functional characterization will be performed at the contractor's laboratory. The anticipated period of performance is eighteen (18) months from the date of award. This acquisition is being conducted as a commercial service acquisition under RFO FAR Part 12. The Government's decision to restrict competition is documented pursuant to RFO FAR 12.102(a). Market research identified OrganoTherapeutics SARL as the only source capable of satisfying the Government's complete requirement for both the required human hindbrain organoids and associated functional assay services. This notice is not intended to restrict consideration of any responsible source capable of meeting the Government's complete requirement. All responsible sources may submit a quotation and supporting capability information by the response date identified in this notice. Any timely response demonstrating the capability to satisfy the Government's complete requirement will be considered by the Contracting Officer prior to award. NAICS: 541714 PSC: B504 – Special Studies/Analysis – Chemical/Biological Place of Delivery: FDA White Oak Campus, Silver Spring, Maryland Place of Service Performance: Contractor's laboratory

Similar open contracts

Metadata

Notice ID
0a2d3e56451c4afa948835a62000bb09
Full path
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.FOOD AND DRUG ADMINISTRATION.FDA OFFICE OF ACQ GRANT SVCS
Office code
Ingested
Sep 13, 2026
Updated
Sep 13, 2026